It is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist)
Helal Egyptian Liver Journal .2025;[Epub] CrossRef Evaluation of triponderal mass index in predicting metabolic associated fatty liver disease in obese children Yavuz zer, Ersin Ulu, Emine Yurdakul Ertrk Pediatrics International .2025;[Epub] CrossRef Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study Dan Ye, Haifen Ma, Jingjing Zhou, Jiaofeng Wang, Jiaheng Shi, Jie Chen, Zhijun Bao, Xiaona Hu BMC Gastroenterology .2025;[Epub] CrossRef Implementation of noninvasive liver disease screening tools in primary care Klaudia Nowak, Adrian Nowak, Aleksandra Jaboska, Anna Potaczek, Julia Salacha, Natalia Dardziska, Jakub Janczura Korean Journal of Family Medicine .2025
Side effects: Both medications share a very similar side effect profile, largely because they influence digestion and appetite
CNS Drugs 21(Suppl
